Literature DB >> 376555

Thrombin-induced platelet secretion. Further evidence for a specific pathway.

M A Shuman, M Botney, J W Fenton.   

Abstract

We have studied the interaction between thrombin and washed, human platelets using prostacyclin, a reversible inhibitor of platelet secretion. The effect of thrombin is limited to those reactions that are not inhibited by an increased concentration of platelet cyclic adenosine 3',5'-monophosphate, because prostacyclin is a potent inducer of the latter. Prostacyclin-treated platelets were briefly (15-30 s) exposed to low concentrations of human thrombin (0.01-0.2 U/ml). After removal of the prostacyclin and thrombin, the platelets were incubated with fresh thrombin. Although they had not undergone the release reaction after the first thrombin incubation, these platelets had a diminished capacity to secrete [(3)H]serotonin when exposed to thrombin the second time. Refractoriness was concentration dependent: the higher the initial thrombin concentration, the greater the degree of inhibition of serotonin secretion on subsequent thrombin exposure. Inhibition was closely related to the ability of thrombin to induce platelet secretion and not to its esterase or fibrinogen clotting activity. Diisopropyl fluorophosphate-inactive thrombin did not induce refractoriness. Refractoriness to thrombin did not increase when the time of the initial incubation with thrombin was lengthened, nor was it reversible.INHIBITION WAS THROMBIN SPECIFIC: serotonin secretion induced by collagen, wheat germ agglutinin, and the ionophore A23187 was minimally affected. For an equivalent amount of thrombin bound, a decrease was observed in serotonin secretion by thrombin-pretreated platelets compared to control platelets. Thus, there is at least one step in the secretory pathway between thrombin binding and regulation of adenylate cyclase. This step appears to transmit the signal that leads to extrusion of intracellular granular contents.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 376555      PMCID: PMC372070          DOI: 10.1172/JCI109416

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  alpha-Adrenergic receptors in rat parotid cells. II. Desensitization of receptor binding sites and potassium release.

Authors:  W J Strittmatter; J N Davis; R J Lefkowitz
Journal:  J Biol Chem       Date:  1977-08-10       Impact factor: 5.157

2.  Morphology and enumeration of human blood platelets.

Authors:  G BRECHER; E P CRONKITE
Journal:  J Appl Physiol       Date:  1950-12       Impact factor: 3.531

3.  Equilibrium binding of thrombin to platelets.

Authors:  B M Martin; W W Wasiewski; J W Fenton; T C Detwiler
Journal:  Biochemistry       Date:  1976-11-02       Impact factor: 3.162

4.  Release of 14C-serotonin during initial platelet changes induced by thrombin, collagen, or A23187.

Authors:  M A Packham; M A Guccione; J P Greenberg; R L Kinlough-Rathbone; J F Mustard
Journal:  Blood       Date:  1977-11       Impact factor: 22.113

5.  Effect of repeated treatment of rabbit platelets with low concentrations of thrombin on their function, metabolism and survival.

Authors:  H J Reimers; M A Packham; R L Kinlough-Rathbone; J F Mustard
Journal:  Br J Haematol       Date:  1973-11       Impact factor: 6.998

6.  Rapid and easy preparation of prostacyclin.

Authors:  K C Nicolaou; W E Bernette; B P Gasic; R L Magolda; W J Sipio; M J Silver; J B Smith; C M Ingerman
Journal:  Lancet       Date:  1977-05-14       Impact factor: 79.321

7.  Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides.

Authors:  R J Gryglewski; S Bunting; S Moncada; R J Flower; J R Vane
Journal:  Prostaglandins       Date:  1976-11

8.  Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions.

Authors:  M Minkes; N Stanford; M M Chi; G J Roth; A Raz; P Needleman; P W Majerus
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

9.  Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets.

Authors:  J E Tateson; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1977-03

10.  The effects of thrombin on adenyl cyclase activity and a membrane protein from human platelets.

Authors:  G N Brodie; N L Baenziger; L R Chase; P W Majerus
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

View more
  5 in total

1.  Ionophore A23187 induces a refractory state in thrombin-activated release of inositol phosphates.

Authors:  G Moscat; F Moreno; S Iglesias; P Garcia-Barreno; A M Municio
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

2.  Thrombin-induced phosphoinositide hydrolysis in platelets. Receptor occupancy and desensitization.

Authors:  E M Huang; T C Detwiler
Journal:  Biochem J       Date:  1987-02-15       Impact factor: 3.857

3.  Mice lacking the thrombin receptor, PAR1, have normal skin wound healing.

Authors:  A J Connolly; D Y Suh; T K Hunt; S R Coughlin
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

4.  The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors.

Authors:  D Salvemini; W Radziszewski; R Korbut; J Vane
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

5.  Cathepsin G and thrombin: evidence for two different platelet receptors.

Authors:  M A Selak
Journal:  Biochem J       Date:  1994-01-15       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.